Nanjing Leads Biolabs Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9887, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Nanjing Leads Biolabs Co. news
We have not published a story on Nanjing Leads Biolabs Co. yet. When there is news, it will appear here.
Questions about Nanjing Leads Biolabs Co.
What is the ticker symbol of Nanjing Leads Biolabs Co.?
Nanjing Leads Biolabs Co., Ltd. trades under the ticker 9887 on HKEX.
Where is Nanjing Leads Biolabs Co. listed?
Nanjing Leads Biolabs Co., Ltd. is listed on HKEX.
Which country or territory is Nanjing Leads Biolabs Co. listed under?
Our directory records Nanjing Leads Biolabs Co., Ltd. under China.
What does Nanjing Leads Biolabs Co. do?
Our directory classifies Nanjing Leads Biolabs Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Nanjing Leads Biolabs Co.?
The ISIN recorded for Nanjing Leads Biolabs Co., Ltd. is CNE1000070H8.
Does aibio.space cover Nanjing Leads Biolabs Co.?
aibio.space lists Nanjing Leads Biolabs Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to Nanjing Leads Biolabs Co.?
Companies in our directory listed in the same country and business area as Nanjing Leads Biolabs Co.: Sinocelltech Group, Chongqing Zhifei Biological Products Co., Walvax Biotechnology Co., Qingdao Vland Biotech INC., Shaanxi Micot Pharmaceutical Technology Co., Hualan Biological Engineering.
Investor discussion: Nanjing Leads Biolabs Co.
Members talk about Nanjing Leads Biolabs Co. (9887). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Nanjing Leads Biolabs Co., newest first. Each line links the filing it comes from.
Financings
Share or debt issue: (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS;
(2) 2025 FINAL FINANCIAL REPORT;
(3) 2025 ANNUAL REPORT;
(4) 2025 PROFIT DISTRIBUTION PLAN;
(5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR;
(6) RE-APPOINTMENT OF AUDITOR;
(7) 2026 DIRECTORS REMUNERATION PLAN;
(8) GENERAL MANDATE TO ISSUE NEW SHARES;
(9) GENERAL MANDATE TO REPURCHASE H SHARES;
(10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
AND
NOTICE OF THE ANNUAL GENERAL MEETING. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:9887 on TradingView.
Listing details
Nanjing Leads Biolabs Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9887, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio